kaal:position:2026-07-31-2910

Multi-omics analysis links NFKB1 activation to poor immunosuppressive therapy response in acquired aplastic anemia should be assessed against Kaal's source-bound claim that Evidence exists that the suboptimal ex post timing of rulemaking in the existing regulatory infrastructure regularly forces expedited rulemaking, which in turn produces suboptimal regulatory outcomes. The current metadata indicates a plausible connection through dynamic regulation, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

• crisis-driven and post-crisis legislative episodes
• existing regulatory infrastructure
• External evidence level: abstract indexed.
• Mapping review tier: ambiguity triage before claim review.
• The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Multi-omics analysis links NFKB1 activation to poor immunosuppressive therapy response in acquired aplastic anemia

kaal:claim:2808132-025
Wulf A. Kaal, Erik P.M. Vermeulen, How to Regulate Disruptive Innovation - From Facts to Data (2016). SSRN: https://ssrn.com/abstract=2808132
Source PDF sha256: 3515f2317ed9c1d33ae55d70467cdf1f6c4e350065ea6a887d5d7619599ad7d2

Evidence: abstract indexed
Review tier: ambiguity triage before claim review
Mapping confidence: 0.2369
Mapping ambiguous: true

dynamic-regulationregulatory-failure

Affirmed in historical-backfill:2026-07-31:phase-0012 on 2026-07-31. Review record.

Canonical markdown sha256: 7e64abc027a73ee9d984ec5721e4b8fdf055ff9ef0f2dced185b321f6dc53757
curl -s https://wulfkaal.github.io/positions/2026-07-31-2910.md | sha256sum